Company
United StatesPublic company, NASDAQ: PTGXProtagonist Therapeutics Inc (NASDAQ: PTGX), Newark, CA – FDA Inspections
Inspection records and compliance data for Protagonist Therapeutics Inc in Newark, CA. 1 FDA inspection on record, 1 Form 483, last inspected April 03, 2026. Publicly traded as NASDAQ: PTGX.
Company Profile
This profile covers Protagonist Therapeutics Inc based in Newark, CA, United States.
FDA Inspection History
- FDA inspections
- 1
- OAI
- 0
- VAI
- 0
- NAI
- 0
- Unclassified
- 1
- Form 483s
- 1
- Warning letters
- 0
Inspected April 3, 2026.
Most cited issue areas
- General responsibilities of sponsors1 inspection
FDA inspections (1)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| April 3, 2026 | Not classified | Human Drugs · Bioresearch Monitoring | 1311710 |
FDA documents
Form 483s (1)
People (1)
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
Protagonist Therapeutics Inc
Stock ticker
PTGX
Exchange
NASDAQ
Share price
$134.38
Market cap
$8.8B
Price as of
November 13, 2026
FEI Number
3013745424
Address
7707 Gateway Blvd Ste 140, Newark, CA 94560-1160, United States
Country
United States
ID: 5c51bacb-7fdd-4bbd-aa5b-5cf279320f4d